首页 > 最新文献

Circulation: Genomic and Precision Medicine最新文献

英文 中文
Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial.
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-31 DOI: 10.1161/CIRCGEN.125.005100
Milind Y Desai, Anjali Owens, Sara Saberi, Andrew Wang, Kathy Wolski, Paul C Cremer, Neal K Lakdawala, Albree Tower-Rader, Mark Zenker, Mark Sherrid, Jeffrey B Geske, David Fermin, Srihari S Naidu, Kathy Lampl, Steven E Nissen
{"title":"Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial.","authors":"Milind Y Desai, Anjali Owens, Sara Saberi, Andrew Wang, Kathy Wolski, Paul C Cremer, Neal K Lakdawala, Albree Tower-Rader, Mark Zenker, Mark Sherrid, Jeffrey B Geske, David Fermin, Srihari S Naidu, Kathy Lampl, Steven E Nissen","doi":"10.1161/CIRCGEN.125.005100","DOIUrl":"10.1161/CIRCGEN.125.005100","url":null,"abstract":"","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e005100"},"PeriodicalIF":6.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
On Penetrance Estimation in Family, Clinical, and Population Cohorts.
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-28 DOI: 10.1161/CIRCGEN.124.004816
Marija Zaicenoka, Vasily E Ramensky, Anna V Kiseleva, Anna A Bukaeva, Anastasia V Blokhina, Alexandra I Ershova, Alexey N Meshkov, Oxana M Drapkina

In recent years, there has been a considerable influx of publications assessing the penetrance of pathogenic variants associated with monogenic diseases with dominant inheritance. As large and diverse groups have been sequenced, it has become clear that incomplete penetrance is common to most hereditary diseases, as numerous molecular, genetic, or environmental factors can cause clinical diversity among the carriers of the same variant. In this review, we discuss some of these factors and focus on the existing approaches to estimating penetrance, depending on the data available and their application to different data sets. We also list some currently available large-scale data sets with penetrance estimates.

{"title":"On Penetrance Estimation in Family, Clinical, and Population Cohorts.","authors":"Marija Zaicenoka, Vasily E Ramensky, Anna V Kiseleva, Anna A Bukaeva, Anastasia V Blokhina, Alexandra I Ershova, Alexey N Meshkov, Oxana M Drapkina","doi":"10.1161/CIRCGEN.124.004816","DOIUrl":"https://doi.org/10.1161/CIRCGEN.124.004816","url":null,"abstract":"<p><p>In recent years, there has been a considerable influx of publications assessing the penetrance of pathogenic variants associated with monogenic diseases with dominant inheritance. As large and diverse groups have been sequenced, it has become clear that incomplete penetrance is common to most hereditary diseases, as numerous molecular, genetic, or environmental factors can cause clinical diversity among the carriers of the same variant. In this review, we discuss some of these factors and focus on the existing approaches to estimating penetrance, depending on the data available and their application to different data sets. We also list some currently available large-scale data sets with penetrance estimates.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004816"},"PeriodicalIF":6.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study. 扩张型心肌病患者及其一级亲属的酒精暴露:DCM 精准医学研究
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-28 DOI: 10.1161/CIRCGEN.124.004946
Javier Jimenez, Hanyu Ni, Stuart D Katz, Garrie J Haas, Jinwen Cao, Muni Rubens, Sandra Chaparro, Anshul Saxena, Mark Hofmeyer, Evan Kransdorf, Gregory A Ewald, Alanna A Morris, Anjali Owens, Brian Lowes, Douglas Stoller, W H Wilson Tang, Palak Shah, Jane E Wilcox, Frank Smart, Jessica Wang, Stephen S Gottlieb, Daniel P Judge, Jonathan O Mead, Natalie Hurst, Patricia K Parker, Gordon S Huggins, Elizabeth Jordan, Daniel D Kinnamon, Ray E Hershberger

Background: Whether prolonged and excessive alcohol consumption contributes to dilated cardiomyopathy (DCM) remains uncertain. This study aimed to describe the prevalence of alcohol use in patients with DCM and their first-degree relatives (FDRs) and determine if cumulative alcohol exposure associates with DCM/partial DCM or modifies the association of DCM with DCM-relevant rare variants.

Methods: All probands had DCM; FDRs were classified as with or without DCM or partial DCM. Alcohol exposure was measured with the Alcohol Use Disorder Identification Test-Consumption questionnaire and years of drinking. Rare variants in 36 DCM genes were classified as pathogenic, likely pathogenic, or variants of uncertain significance (pathogenic, likely pathogenic, variant of uncertain significance). Generalized linear mixed models were used to assess the association of DCM/partial DCM with alcohol use among FDRs.

Results: DCM/partial DCM was found in 21.8% of 1373 FDRs of 1148 DCM probands. The prevalence of former or current alcohol use was 68% for probands and 70% for FDRs. About 30% of probands and 37% of FDRs had positive Alcohol Use Disorder Identification Test-Consumption scores, indicating moderate or heavy drinking. Among FDRs, DCM/partial DCM was associated with the presence of pathogenic/likely pathogenic variants in DCM genes (odds ratio, 3.51 [95% CI, 2.33-5.29]) but not with alcohol exposure. Cumulative alcohol exposure was not found to modify the association between DCM/partial DCM and these variants (P=0.55).

Conclusions: Alcohol use was frequent among probands and FDRs. This study did not provide evidence supporting an association of cumulative alcohol exposure with DCM/partial DCM or a modifying effect of alcohol use on the association of DCM with DCM-relevant rare variants.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03037632.

{"title":"Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.","authors":"Javier Jimenez, Hanyu Ni, Stuart D Katz, Garrie J Haas, Jinwen Cao, Muni Rubens, Sandra Chaparro, Anshul Saxena, Mark Hofmeyer, Evan Kransdorf, Gregory A Ewald, Alanna A Morris, Anjali Owens, Brian Lowes, Douglas Stoller, W H Wilson Tang, Palak Shah, Jane E Wilcox, Frank Smart, Jessica Wang, Stephen S Gottlieb, Daniel P Judge, Jonathan O Mead, Natalie Hurst, Patricia K Parker, Gordon S Huggins, Elizabeth Jordan, Daniel D Kinnamon, Ray E Hershberger","doi":"10.1161/CIRCGEN.124.004946","DOIUrl":"10.1161/CIRCGEN.124.004946","url":null,"abstract":"<p><strong>Background: </strong>Whether prolonged and excessive alcohol consumption contributes to dilated cardiomyopathy (DCM) remains uncertain. This study aimed to describe the prevalence of alcohol use in patients with DCM and their first-degree relatives (FDRs) and determine if cumulative alcohol exposure associates with DCM/partial DCM or modifies the association of DCM with DCM-relevant rare variants.</p><p><strong>Methods: </strong>All probands had DCM; FDRs were classified as with or without DCM or partial DCM. Alcohol exposure was measured with the Alcohol Use Disorder Identification Test-Consumption questionnaire and years of drinking. Rare variants in 36 DCM genes were classified as pathogenic, likely pathogenic, or variants of uncertain significance (pathogenic, likely pathogenic, variant of uncertain significance). Generalized linear mixed models were used to assess the association of DCM/partial DCM with alcohol use among FDRs.</p><p><strong>Results: </strong>DCM/partial DCM was found in 21.8% of 1373 FDRs of 1148 DCM probands. The prevalence of former or current alcohol use was 68% for probands and 70% for FDRs. About 30% of probands and 37% of FDRs had positive Alcohol Use Disorder Identification Test-Consumption scores, indicating moderate or heavy drinking. Among FDRs, DCM/partial DCM was associated with the presence of pathogenic/likely pathogenic variants in DCM genes (odds ratio, 3.51 [95% CI, 2.33-5.29]) but not with alcohol exposure. Cumulative alcohol exposure was not found to modify the association between DCM/partial DCM and these variants (<i>P</i>=0.55).</p><p><strong>Conclusions: </strong>Alcohol use was frequent among probands and FDRs. This study did not provide evidence supporting an association of cumulative alcohol exposure with DCM/partial DCM or a modifying effect of alcohol use on the association of DCM with DCM-relevant rare variants.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT03037632.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004946"},"PeriodicalIF":6.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dysmorphology-Based Prediction Model for Genetic Disorders in Infants With Congenital Heart Disease. 基于畸形的先天性心脏病婴儿遗传疾病预测模型
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-28 DOI: 10.1161/CIRCGEN.124.004895
Benjamin M Helm, Leah Wetherill, Benjamin J Landis, Stephanie M Ware

Background: Genetic disorders are prevalent in patients with congenital heart disease (CHD), but genetic evaluations are underutilized and nonstandardized. We sought to quantify a dysmorphology score and develop phenotype-based prediction models for genetic diagnoses in CHD.

Methods: We used a test-negative case-control study of inpatient infants (<1 year) with CHD undergoing standardized genetic evaluations. We quantified a novel dysmorphology score and combined it with other clinical variables used in multivariable logistic regression models to predict genetic diagnoses identified by genetic testing.

Results: Of 1008 patients, 24.1% (243/1008) had genetic diagnoses identified. About half of the cohort were either nondysmorphic or mildly dysmorphic with dysmorphology scores ≤2. There were higher dysmorphology scores according to CHD class (P=0.0007), extracardiac anomaly-positive status (P<0.0001), female sex (P=0.05), and genetic diagnosis identified (P<0.0001). Multivariable logistic regression models quantified this effect further: each +1 increase in the dysmorphology score was associated with a 17% to 20% increased risk of genetic diagnoses (odds ratios, 1.17-1.20, P<0.0001). Extracardiac anomaly-positive status remained a stronger predictor of genetic diagnoses (odds ratios, 2.81-3.39). Nonetheless, about 10% of the cohort were minimally dysmorphic (dysmorphology scores ≤2), had isolated CHD, and were found to have genetic diagnoses, indicating that dysmorphology-based screening can be used to risk-stratify but not exclude genetic diagnoses.

Conclusions: The dysmorphology score is a novel screen for patients with CHD at high risk of having genetic diagnoses identified by genetic testing, including disorders not easily recognized by clinicians. We used these results to develop predicted probability plots for genetic diagnoses in patients with CHD.

{"title":"Dysmorphology-Based Prediction Model for Genetic Disorders in Infants With Congenital Heart Disease.","authors":"Benjamin M Helm, Leah Wetherill, Benjamin J Landis, Stephanie M Ware","doi":"10.1161/CIRCGEN.124.004895","DOIUrl":"https://doi.org/10.1161/CIRCGEN.124.004895","url":null,"abstract":"<p><strong>Background: </strong>Genetic disorders are prevalent in patients with congenital heart disease (CHD), but genetic evaluations are underutilized and nonstandardized. We sought to quantify a dysmorphology score and develop phenotype-based prediction models for genetic diagnoses in CHD.</p><p><strong>Methods: </strong>We used a test-negative case-control study of inpatient infants (<1 year) with CHD undergoing standardized genetic evaluations. We quantified a novel dysmorphology score and combined it with other clinical variables used in multivariable logistic regression models to predict genetic diagnoses identified by genetic testing.</p><p><strong>Results: </strong>Of 1008 patients, 24.1% (243/1008) had genetic diagnoses identified. About half of the cohort were either nondysmorphic or mildly dysmorphic with dysmorphology scores ≤2. There were higher dysmorphology scores according to CHD class (<i>P</i>=0.0007), extracardiac anomaly-positive status (<i>P</i><0.0001), female sex (<i>P</i>=0.05), and genetic diagnosis identified (<i>P</i><0.0001). Multivariable logistic regression models quantified this effect further: each +1 increase in the dysmorphology score was associated with a 17% to 20% increased risk of genetic diagnoses (odds ratios, 1.17-1.20, <i>P</i><0.0001). Extracardiac anomaly-positive status remained a stronger predictor of genetic diagnoses (odds ratios, 2.81-3.39). Nonetheless, about 10% of the cohort were minimally dysmorphic (dysmorphology scores ≤2), had isolated CHD, and were found to have genetic diagnoses, indicating that dysmorphology-based screening can be used to risk-stratify but not exclude genetic diagnoses.</p><p><strong>Conclusions: </strong>The dysmorphology score is a novel screen for patients with CHD at high risk of having genetic diagnoses identified by genetic testing, including disorders not easily recognized by clinicians. We used these results to develop predicted probability plots for genetic diagnoses in patients with CHD.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004895"},"PeriodicalIF":6.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DNA Damage Response and Repair Genes and Anthracycline-Induced Cardiomyopathy in Childhood Cancer Survivors: A Report From the Children's Oncology Group and the Childhood Cancer Survivor Study. 儿童癌症幸存者的 DNA 损伤反应和修复基因与蒽环类药物诱发的心肌病:儿童肿瘤学小组和儿童癌症幸存者研究报告》(Childhood's Oncology Group and the Childhood Cancer Survivor Study)。
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-28 DOI: 10.1161/CIRCGEN.124.004813
Xuexia Wang, Purnima Singh, Romina B Cejas, Liting Zhou, Noha Sharafeldin, Patrick J Trainor, Wendy Landier, Changde Cheng, Lindsey Hageman, Fan Wang, Yadav Sapkota, Yutaka Yasui, Melissa M Hudson, Eric J Chow, Saro H Armenian, Joseph P Neglia, Douglas S Hawkins, Jill P Ginsberg, Paul W Burridge, Gregory T Armstrong, Smita Bhatia

Background: Anthracyclines induce cardiotoxicity via DNA double-strand breaks and reactive oxygen species formation, resulting in cardiomyocyte dysfunction. The role of DNA damage response/repair (DDR) genes in anthracycline-induced cardiomyopathy remains unstudied.

Methods: We conducted a gene-based and pathway-based analysis to examine the main effect and gene-anthracycline interaction effect between DDR genes and anthracycline-induced cardiomyopathy. A discovery analysis performed with a matched case-control set of anthracycline-exposed non-Hispanic White childhood cancer survivors from Children's Oncology Group-ALTE03N1 (113 cases; 226 controls) was replicated using a cohort of anthracycline-exposed non-Hispanic White childhood cancer survivors from the Childhood Cancer Survivor Study cohort (n=1658; 97 cases). Functional analyses were performed by examining the response to doxorubicin of human-induced pluripotent stem cell-derived cardiomyocytes with CRISPR/Cas9-mediated knockout of prioritized genes.

Results: Successfully replicated DDR genes demonstrating main-effect association included FANCC (P=0.037) and XRCC5 (P=0.001) and demonstrated gene-anthracycline interaction included MGMT (P=0.041). Knockouts of FANCC and MGMT in human-induced pluripotent stem cell-derived cardiomyocytes demonstrated significant resistance to doxorubicin, suggesting that these genes play a role in anthracycline-induced cardiotoxicity. Successfully replicated DDR pathways demonstrating main-effect association included base excision repair (P=2.7×10-4); role of BRCA1 in DDR (P=9.2×10-5); p53 signaling (P<1×10-16); role of checkpoint kinases proteins in cell cycle checkpoint control (P<1×10-16); mismatch repair (P<10-16); and double-strand break repair by homologous recombination (P<1×10-16). Successfully replicated DDR pathways demonstrating significant interaction effects included role of BRCA1 in DDR (P=1.4×10-4); p53 signaling (P<1×10-16); the role of checkpoint kinases proteins in cell cycle checkpoint control (P<1×10-16); mismatch repair (P<1×10-16); cell cycle: G2/M DNA damage checkpoint regulation (P=0.002); double-strand break repair by homologous recombination (P=0.009); GADD45 signaling (P=4.8×10-4); and cell cycle control of chromosomal replication (P=4.5×10-4).

Conclusions: These findings provide evidence for the role of DDR genes and pathways in anthracycline-induced cardiomyopathy and provide a framework for targeted therapeutic interventions.

背景:蒽环类药物通过 DNA 双链断裂和活性氧形成诱发心脏毒性,导致心肌细胞功能障碍。DNA损伤应答/修复(DDR)基因在蒽环类药物诱导的心肌病中的作用仍未得到研究:我们进行了基于基因和通路的分析,以研究 DDR 基因与蒽环类药物诱发的心肌病之间的主效应和基因与蒽环类药物之间的交互效应。我们使用儿童癌症幸存者研究队列中接触过蒽环类药物的非西班牙裔白人儿童癌症幸存者队列(n=1658;97例),对儿童肿瘤学组-ALTE03N1中接触过蒽环类药物的非西班牙裔白人儿童癌症幸存者的匹配病例对照集(113例;226例对照)进行了发现性分析。通过CRISPR/Cas9介导的优先基因敲除,对人类诱导多能干细胞衍生的心肌细胞对多柔比星的反应进行了功能分析:结果:成功复制的DDR基因与主效应相关,包括FANCC(P=0.037)和XRCC5(P=0.001),基因与四环素的相互作用包括MGMT(P=0.041)。在人类诱导多能干细胞衍生的心肌细胞中敲除FANCC和MGMT,显示出对多柔比星的显著抗性,表明这些基因在蒽环类诱导的心脏毒性中发挥作用。成功复制的显示主效应关联的 DDR 途径包括碱基切除修复(P=2.7×10-4);BRCA1 在 DDR 中的作用(P=9.2×10-5);p53 信号传导(P-16);检查点激酶蛋白在细胞周期检查点控制中的作用(P-16);错配修复(P-16);同源重组的双链断裂修复(P-16)。成功复制的具有显著交互效应的 DDR 途径包括 BRCA1 在 DDR 中的作用(P=1.4×10-4);p53 信号传导(P1×10-16);检查点激酶蛋白在细胞周期检查点控制中的作用(P-16);错配修复(P-16);细胞周期:G2/M DNA损伤检查点调控(P=0.002);同源重组的双链断裂修复(P=0.009);GADD45信号传导(P=4.8×10-4);以及染色体复制的细胞周期控制(P=4.5×10-4):这些发现为DDR基因和通路在蒽环类诱导的心肌病中的作用提供了证据,并为靶向治疗干预提供了框架。
{"title":"DNA Damage Response and Repair Genes and Anthracycline-Induced Cardiomyopathy in Childhood Cancer Survivors: A Report From the Children's Oncology Group and the Childhood Cancer Survivor Study.","authors":"Xuexia Wang, Purnima Singh, Romina B Cejas, Liting Zhou, Noha Sharafeldin, Patrick J Trainor, Wendy Landier, Changde Cheng, Lindsey Hageman, Fan Wang, Yadav Sapkota, Yutaka Yasui, Melissa M Hudson, Eric J Chow, Saro H Armenian, Joseph P Neglia, Douglas S Hawkins, Jill P Ginsberg, Paul W Burridge, Gregory T Armstrong, Smita Bhatia","doi":"10.1161/CIRCGEN.124.004813","DOIUrl":"10.1161/CIRCGEN.124.004813","url":null,"abstract":"<p><strong>Background: </strong>Anthracyclines induce cardiotoxicity via DNA double-strand breaks and reactive oxygen species formation, resulting in cardiomyocyte dysfunction. The role of DNA damage response/repair (DDR) genes in anthracycline-induced cardiomyopathy remains unstudied.</p><p><strong>Methods: </strong>We conducted a gene-based and pathway-based analysis to examine the main effect and gene-anthracycline interaction effect between DDR genes and anthracycline-induced cardiomyopathy. A discovery analysis performed with a matched case-control set of anthracycline-exposed non-Hispanic White childhood cancer survivors from Children's Oncology Group-ALTE03N1 (113 cases; 226 controls) was replicated using a cohort of anthracycline-exposed non-Hispanic White childhood cancer survivors from the Childhood Cancer Survivor Study cohort (n=1658; 97 cases). Functional analyses were performed by examining the response to doxorubicin of human-induced pluripotent stem cell-derived cardiomyocytes with CRISPR/Cas9-mediated knockout of prioritized genes.</p><p><strong>Results: </strong>Successfully replicated DDR genes demonstrating main-effect association included <i>FANCC</i> (<i>P</i>=0.037) and <i>XRCC5</i> (<i>P</i>=0.001) and demonstrated gene-anthracycline interaction included <i>MGMT</i> (<i>P</i>=0.041). Knockouts of <i>FANCC</i> and <i>MGMT</i> in human-induced pluripotent stem cell-derived cardiomyocytes demonstrated significant resistance to doxorubicin, suggesting that these genes play a role in anthracycline-induced cardiotoxicity. Successfully replicated DDR pathways demonstrating main-effect association included base excision repair (<i>P</i>=2.7×10<sup>-4</sup>); role of <i>BRCA1</i> in DDR (<i>P</i>=9.2×10<sup>-5</sup>); p53 signaling (<i>P</i><1×10<sup>-16</sup>); role of checkpoint kinases proteins in cell cycle checkpoint control (<i>P</i><1×10<sup>-16</sup>); mismatch repair (<i>P</i><10<sup>-16</sup>); and double-strand break repair by homologous recombination (<i>P</i><1×10<sup>-16</sup>). Successfully replicated DDR pathways demonstrating significant interaction effects included role of <i>BRCA1</i> in DDR (<i>P</i>=1.4×10<sup>-4</sup>); p53 signaling (<i>P<</i>1×10<sup>-16</sup>); the role of checkpoint kinases proteins in cell cycle checkpoint control (<i>P</i><1×10<sup>-16</sup>); mismatch repair (<i>P</i><1×10<sup>-16</sup>); cell cycle: G2/M DNA damage checkpoint regulation (<i>P</i>=0.002); double-strand break repair by homologous recombination (<i>P</i>=0.009); <i>GADD45</i> signaling (<i>P</i>=4.8×10<sup>-4</sup>); and cell cycle control of chromosomal replication (<i>P</i>=4.5×10<sup>-4</sup>).</p><p><strong>Conclusions: </strong>These findings provide evidence for the role of DDR genes and pathways in anthracycline-induced cardiomyopathy and provide a framework for targeted therapeutic interventions.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004813"},"PeriodicalIF":6.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Disclosing a Polygenic Risk Score for Coronary Heart Disease on Adverse Cardiovascular Events.
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-28 DOI: 10.1161/CIRCGEN.124.004968
Mohammadreza Naderian, Marwan E Hamed, Ali A Vaseem, Kristjan Norland, Ozan Dikilitas, Azin Teymourzadeh, Kent R Bailey, Iftikhar J Kullo

Background: In the MI-GENES clinical trial (URL: https://www.clinicaltrials.gov; Unique identifier: NCT01936675), participants at intermediate risk of coronary heart disease (CHD) were randomized to receive a Framingham risk score (Framingham risk score group, n=103) or an integrated risk score (integrated risk score group [IRSg], n=104) that additionally included a polygenic risk score. After 6 months, IRSg participants had higher statin initiation and lower low-density lipoprotein cholesterol. We conducted a post hoc 10-year follow-up analysis to investigate whether disclosure of a polygenic risk score for CHD was associated with a reduction in major adverse cardiovascular events (MACE).

Methods: Participants were followed from randomization in October 2013 to September 2023 to ascertain MACE, testing for CHD, and changes in risk factors. The primary outcome was time to first MACE, defined as cardiovascular death, nonfatal myocardial infarction, coronary revascularization, and nonfatal stroke. Statistical analyses included Cox proportional hazards regression and linear mixed-effects models.

Results: We followed all participants who completed the trial, 100 in Framingham risk score group and 103 in IRSg (mean age at the end of follow-up, 68.2±5.2; 48% male). During a median follow-up of 9.5 years, 9 MACEs occurred in Framingham risk score group and 2 in IRSg (hazard ratio, 0.20 [95% CI, 0.04-0.94]; P=0.042). In Framingham risk score group, 47 (47%) underwent at least 1 diagnostic test for CHD, compared with 30 (29%) in IRSg (hazard ratio, 0.51 [95% CI, 0.32-0.81]; P=0.004). A higher proportion of IRSg participants were on statin therapy during the first 4 years postrandomization and had a greater reduction in low-density lipoprotein cholesterol for up to 3 years postrandomization. No significant differences were observed between 2 groups in other traditional cardiovascular risk factors during follow-up.

Conclusions: Disclosure of an integrated risk score that included a polygenic risk score to individuals at intermediate risk for CHD was associated with lower MACE incidence after 10 years, likely due to higher statin initiation, leading to lower low-density lipoprotein cholesterol levels.

{"title":"Effect of Disclosing a Polygenic Risk Score for Coronary Heart Disease on Adverse Cardiovascular Events.","authors":"Mohammadreza Naderian, Marwan E Hamed, Ali A Vaseem, Kristjan Norland, Ozan Dikilitas, Azin Teymourzadeh, Kent R Bailey, Iftikhar J Kullo","doi":"10.1161/CIRCGEN.124.004968","DOIUrl":"10.1161/CIRCGEN.124.004968","url":null,"abstract":"<p><strong>Background: </strong>In the MI-GENES clinical trial (URL: https://www.clinicaltrials.gov; Unique identifier: NCT01936675), participants at intermediate risk of coronary heart disease (CHD) were randomized to receive a Framingham risk score (Framingham risk score group, n=103) or an integrated risk score (integrated risk score group [IRS<sub>g</sub>], n=104) that additionally included a polygenic risk score. After 6 months, IRS<sub>g</sub> participants had higher statin initiation and lower low-density lipoprotein cholesterol. We conducted a post hoc 10-year follow-up analysis to investigate whether disclosure of a polygenic risk score for CHD was associated with a reduction in major adverse cardiovascular events (MACE).</p><p><strong>Methods: </strong>Participants were followed from randomization in October 2013 to September 2023 to ascertain MACE, testing for CHD, and changes in risk factors. The primary outcome was time to first MACE, defined as cardiovascular death, nonfatal myocardial infarction, coronary revascularization, and nonfatal stroke. Statistical analyses included Cox proportional hazards regression and linear mixed-effects models.</p><p><strong>Results: </strong>We followed all participants who completed the trial, 100 in Framingham risk score group and 103 in IRS<sub>g</sub> (mean age at the end of follow-up, 68.2±5.2; 48% male). During a median follow-up of 9.5 years, 9 MACEs occurred in Framingham risk score group and 2 in IRS<sub>g</sub> (hazard ratio, 0.20 [95% CI, 0.04-0.94]; <i>P</i>=0.042). In Framingham risk score group, 47 (47%) underwent at least 1 diagnostic test for CHD, compared with 30 (29%) in IRS<sub>g</sub> (hazard ratio, 0.51 [95% CI, 0.32-0.81]; <i>P</i>=0.004). A higher proportion of IRS<sub>g</sub> participants were on statin therapy during the first 4 years postrandomization and had a greater reduction in low-density lipoprotein cholesterol for up to 3 years postrandomization. No significant differences were observed between 2 groups in other traditional cardiovascular risk factors during follow-up.</p><p><strong>Conclusions: </strong>Disclosure of an integrated risk score that included a polygenic risk score to individuals at intermediate risk for CHD was associated with lower MACE incidence after 10 years, likely due to higher statin initiation, leading to lower low-density lipoprotein cholesterol levels.</p>","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004968"},"PeriodicalIF":6.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined RNA Splicing and Patch-Clamp Analysis Reveal Pathogenicity of Splice-Altering Variants in KCNH2-Related LQTS.
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-25 DOI: 10.1161/CIRCGEN.124.004966
Susan Clasper, Gunjan Trivedi, Kate L Thomson, Claire L S Turner, Smrithi Devaiah, Catherine L Mercer, Amnah Y Bdeir, Jumana Y Al-Aama, Khalid Dagriri, Alex R Hobson, Shankar N Sadagopan, Julian Ormerod, Eszter Szepesvary, Justin Phan, Diane Fatkin, Jamie I Vandenberg, Zahurul A Bhuiyan, Chai-Ann Ng
{"title":"Combined RNA Splicing and Patch-Clamp Analysis Reveal Pathogenicity of Splice-Altering Variants in <i>KCNH2</i>-Related LQTS.","authors":"Susan Clasper, Gunjan Trivedi, Kate L Thomson, Claire L S Turner, Smrithi Devaiah, Catherine L Mercer, Amnah Y Bdeir, Jumana Y Al-Aama, Khalid Dagriri, Alex R Hobson, Shankar N Sadagopan, Julian Ormerod, Eszter Szepesvary, Justin Phan, Diane Fatkin, Jamie I Vandenberg, Zahurul A Bhuiyan, Chai-Ann Ng","doi":"10.1161/CIRCGEN.124.004966","DOIUrl":"https://doi.org/10.1161/CIRCGEN.124.004966","url":null,"abstract":"","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004966"},"PeriodicalIF":6.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Many Journeys Originating at the Same Source to Arrive at Solutions to the Common Problem of High Lipoprotein(a).
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-25 DOI: 10.1161/CIRCGEN.125.005126
Jean Woody Luxama, Joshua W Knowles
{"title":"Many Journeys Originating at the Same Source to Arrive at Solutions to the Common Problem of High Lipoprotein(a).","authors":"Jean Woody Luxama, Joshua W Knowles","doi":"10.1161/CIRCGEN.125.005126","DOIUrl":"https://doi.org/10.1161/CIRCGEN.125.005126","url":null,"abstract":"","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e005126"},"PeriodicalIF":6.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-Scientist Perspective on Developing Genetic Therapies for Marfan Syndrome.
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-25 DOI: 10.1161/CIRCGEN.125.005114
Lauren Testa
{"title":"Patient-Scientist Perspective on Developing Genetic Therapies for Marfan Syndrome.","authors":"Lauren Testa","doi":"10.1161/CIRCGEN.125.005114","DOIUrl":"https://doi.org/10.1161/CIRCGEN.125.005114","url":null,"abstract":"","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e005114"},"PeriodicalIF":6.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Performance of AlphaMissense and Other In Silico Predictors to Determine Pathogenicity of Missense Variants in Sarcomeric Genes.
IF 6 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-03-21 DOI: 10.1161/CIRCGEN.124.004922
Mario Ruiz, Juan Pablo Ochoa, Candela Migoyo-Bettoni, Jorge de la Barrera, Alba Delrio-Lorenzo, Manuel A Fernández-Rojo, Ines Martinez-Martin, Jorge Alegre-Cebollada, Enrique Lara-Pezzi, Fatima Sanchez-Cabo, Pablo Garcia-Pavia
{"title":"Performance of AlphaMissense and Other In Silico Predictors to Determine Pathogenicity of Missense Variants in Sarcomeric Genes.","authors":"Mario Ruiz, Juan Pablo Ochoa, Candela Migoyo-Bettoni, Jorge de la Barrera, Alba Delrio-Lorenzo, Manuel A Fernández-Rojo, Ines Martinez-Martin, Jorge Alegre-Cebollada, Enrique Lara-Pezzi, Fatima Sanchez-Cabo, Pablo Garcia-Pavia","doi":"10.1161/CIRCGEN.124.004922","DOIUrl":"https://doi.org/10.1161/CIRCGEN.124.004922","url":null,"abstract":"","PeriodicalId":10326,"journal":{"name":"Circulation: Genomic and Precision Medicine","volume":" ","pages":"e004922"},"PeriodicalIF":6.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Circulation: Genomic and Precision Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1